NASDAQ : JAZZ
Jazz Pharmaceuticals plc — Key statistics
Healthcare · Biotechnology · Ireland
Last price 215.98 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 14.02B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 14.02B |
| Enterprise Value | 16.23B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 64.91M |
| Shares Outstanding | 64.91M |
| Shares Change (YoY) | +5.40% |
| Shares Change (QoQ) | +4.99% |
| Owned by Insiders (%) | 2.89% |
| Owned by Institutions (%) | 100.83% |
| Float | 62.99M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 14.76 |
| Forward PE | 12.94 |
| PS Ratio | 3.05 |
| Forward PS | 2.87 |
| PB Ratio | 2.91 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 8.81 |
| P/OCF Ratio | 8.44 |
| PEG Ratio | 0.24 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 17.25 |
| EV / Sales | 3.53 |
| EV / EBITDA | 8.42 |
| EV / EBIT | 13.42 |
| EV / FCF | 10.20 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.78 |
| Quick Ratio | 1.38 |
| Debt / Equity | 0.92 |
| Debt / EBITDA | 2.25 |
| Debt / FCF | 2.77 |
| Interest Coverage | 4.67 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 22.11% |
| Return on Assets (ROA) | 6.86% |
| Return on Invested Capital (ROIC) | 17.17% |
| Return on Capital Employed (ROCE) | 13.66% |
| Weighted Average Cost of Capital (WACC) | 5.89% |
| Revenue Per Employee | $1.59M |
| Profits Per Employee | $325,520 |
| Employee Count | 2,890 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 0.84 |
Taxes
| Measure | Value |
|---|
| Income Tax | -213.24M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.37 |
| 52-Week Price Change | +59.13% |
| 50-Day Moving Average | 231.96 |
| 200-Day Moving Average | 216.63 |
| Relative Strength Index (RSI) | 46.38 |
| Average Volume (20 Days) | 830,594 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.86M |
| Short Previous Month | 5.48M |
| Short % of Shares Out | 9.03% |
| Short % of Float | 9.31% |
| Short Ratio (days to cover) | 6.86 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 4.60B |
| Gross Profit | 4.20B |
| Operating Income | 1.21B |
| Pretax Income | 727.51M |
| Net Income | 940.75M |
| EBITDA | 1.93B |
| EBIT | 1.21B |
| Earnings Per Share (EPS) | $14.63 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 2.20B |
| Total Debt | 4.41B |
| Net Cash | -2.21B |
| Net Cash Per Share | -$34.04 |
| Equity (Book Value) | 4.80B |
| Book Value Per Share | 74.10 |
| Working Capital | 1.74B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 1.66B |
| Capital Expenditures | -69.75M |
| Depreciation & Amortization | 718.00M |
| Net Borrowing | -1.03B |
| Free Cash Flow | 1.59B |
| FCF Per Share | $24.51 |
Margins
| Measure | Value |
|---|
| Gross Margin | 91.35% |
| Operating Margin | 26.28% |
| Pretax Margin | 15.81% |
| Profit Margin | 20.45% |
| EBITDA Margin | 41.88% |
| EBIT Margin | 26.28% |
| FCF Margin | 34.58% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -5.40% |
| Shareholder Yield | -5.40% |
| Earnings Yield | 6.78% |
| FCF Yield | 11.35% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $295.36 |
| Price Target Difference | 36.75% |
| Analyst Consensus | Buy |
| Analyst Count | 22 |
| Revenue Growth Forecast (3Y) | 8.54% |
| EPS Growth Forecast (3Y) | 47.12% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.08 |
| Piotroski F-Score | 7 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |